

FORMATO EUROPEO PER
IL CURRICULUM VITAE



INFORMAZIONI PERSONALI

Nome **MARIA CRISTINA MINGARI**

Indirizzo **VIALE DELLE SACRAMENTINE 3/16, 16145 GENOVA**

Telefono **010 3624137**

Fax

E-mail **mariacristina.mingari@unige.it**

Nazionalità **italiana**

Data di nascita **29/06/1952**

ESPERIENZA LAVORATIVA

• Date (da – a)

1976 "Visiting Scientist" University of Alabama, Birmingham, USA

1979 "Visiting Scientist" Harvard University, Boston, USA.

1980-84 "Assistant Member" Ludwig Institute for Cancer Research, Lausanne, Switzerland.

1981-98: Assistant Professor, Medical School, University of Genoa

1998: Associate Professor of Immunopathology, Medical School, University of Genoa.

2000 to date: Full Professor of General Pathology Medical School, University of Genoa,

2000 to date: Director of Immunology Laboratories, Cancer Research Institute (IRCCS A.O.U. San Martino IST)

2002-04: Director of the Department of Oncogenesis, Cancer Research Institute (IRCCS A.O.U. San Martino IST)

• Nome e indirizzo del datore di lavoro

University of Genova and IRCCS Azienda Ospedaliera Universitaria San Martino – IST Istituto Nazionale per la Ricerca sul Cancro

Largo R. Benzi, 10 - 16132 Genova- Italia

• Tipo di azienda o settore

Minister of Health and Minister of School and University

• Tipo di impiego

- Principali mansioni e responsabilità

Professor at the University and UOC Director

ISTRUZIONE E FORMAZIONE

- Date (da – a)

2000 to date: Full Professor, MED04, General Pathology

1998 - 2000: Associate professor, MED04, General Pathology

1980-1998: Assistant Professor University of Genova

1975: PhD in Biology (110/110 cum laude)

CAPACITÀ E COMPETENZE

PERSONALI

Acquisite nel corso della vita e della carriera ma non necessariamente riconosciute da certificati e diplomi ufficiali.

MADRELINGUA

ITALIANO

ALTRE LINGUE

INGLESE

- Capacità di lettura
- Capacità di scrittura
- Capacità di espressione orale

eccellente

buono

buono

CAPACITÀ E COMPETENZE

RELAZIONALI

Vivere e lavorare con altre persone, in ambiente multiculturale, occupando posti in cui la comunicazione è importante e in situazioni in cui è essenziale lavorare in squadra (ad es. cultura e sport), ecc.

[Descrivere tali competenze e indicare dove sono state acquisite.]

CAPACITÀ E COMPETENZE

ORGANIZZATIVE

Ad es. coordinamento e amministrazione di persone, progetti, bilanci; sul posto di lavoro, in attività di volontariato (ad es. cultura e sport), a casa, ecc.

Prof. Mingari coordinates the various research lines ongoing in the Immunology Unit . She takes care of different bureaucratic problems and criticality connected with the management of the Unit

She teaches Immunology and General Pathology at the Medical School, coordinates the School of Specialization in General Pathology and Clinical Pathology and she is the director of the PhD programme in Immunology at the University of Genova.

CAPACITÀ E COMPETENZE

TECNICHE

Con computer, attrezzature specifiche, macchinari, ecc.

Prof. Mingari research activity

Prof. Mingari research activity has been mainly focalized on topics in cellular immunology.

Main Contributions: Analysis of lymphocyte subsets and identification of their surface receptor molecules. She also greatly contributed to the development, application and optimization of several different immunological techniques such as monoclonal antibodies production that allowed to obtain new reagents capable of recognizing novel T cells and NK cells surface markers/receptors. The development of high cloning T cell efficiency techniques allowed to study the correlations, at the single cell level, between cell surface phenotype and a given function. She demonstrated that IL-2 functions as an important B cell growth factor and that B cells express, upon activation, an IL-2 receptor (CD25)

identical to that expressed by T lymphocytes (Mingari et al. Nature 1984). She characterized a novel cytotoxic T lymphocyte subpopulation with NK-like activity. She showed that these CTLs may also express HLA-class I-specific inhibitory receptors (iNKR) that can be induced by cytokines (Mingari et al, PNAS, 1996) Importantly, she showed that such iNKR+ CTLs are frequently HLA-E-restricted, thus identifying not only a novel T cell subset but also a relevant new function for the poorly polymorphic HLA-E molecules. More recently she defined the phenotypic and functional properties of NK cells infiltrating human tumors and analyzed the molecular mechanisms by which the tumor microenvironment inhibits NK cell function. In addition, she studied the effect of the decidual microenvironment on lymphoid cell function (reminiscent of the tumor microenvironment) and could show the presence of resident innate lymphoid cells (ILC) other than NK that may play an important regulatory role during pregnancy. The presence of ILC, their precursors and their differentiation potential and function has been documented also in other tissues including tonsils and intestinal lamina propria.

Prof. Mingari is author of over 260 publications "in extenso", most of which in high rank international journals.

Many of such papers are highly cited in the literature as reported by the Institute of Scientific Information (ISI).

GOOGLE SCHOLAR:

Total Citations: over 17.000 Since 2010: over 6.000

H-Index: = 67 Since 2010: 37

CAPACITÀ E COMPETENZE
ARTISTICHE

Musica, scrittura, disegno ecc.

[Descrivere tali competenze e indicare dove sono state acquisite.]

ALTRE CAPACITÀ E COMPETENZE

*Competenze non
precedentemente indicate.*

[Descrivere tali competenze e indicare dove sono state acquisite.]

Prof. Mingari Publications 2008 – 2015

1

Carrega P, Morandi B, Costa R, Frumento G, Forte G, Altavilla G, Ratto GB, Mingari MC, Moretta L, Ferlazzo G.

Natural killer cells infiltrating human nonsmall-cell lung cancer are enriched in CD56^{bright} CD16⁻ cells and display an impaired capability to kill tumor cells.

CANCER 2008112(4):863-75.

2

Scordamaglia F, Balsamo M, Scordamaglia A, Moretta A, Mingari MC, Canonica GW, Moretta L, Vitale M.

Perturbations of natural killer cell regulatory functions in respiratory allergic diseases.

J ALLERGY CLIN IMMUNOL. 200812: 479-485,

3

Avignolo C, Bagnasco L, Biasotti B, Melchiori A, Tomati V, Bauer I, Salis A, Chiossone L, Mingari MC, Orecchia P, Carnemolla B, Neri D, Zardi L, and Parodi S.

Internalization via Antennapedia protein transduction domain of an scFv antibody toward c-Myc protein.

FASEB J. 2008 22:1237-1245

4

Spaggiari GM, Capobianco A, Abdelrazik H, Becchetti F, Mingari MC, Moretta L. Mesenchymal stem cells inhibit natural killer-cell proliferation, cytotoxicity, and cytokine production: role of indoleamine 2,3-dioxygenase and prostaglandin E2.

BLOOD. 2008, 111(3):1327-33

5

Vacca P, Cantoni C, Prato C, Fulcheri E, Moretta A, Moretta L, Mingari M.C.

Regulatory role of NKp44, NKp46, DNAM-1 and NKG2D receptors in the interaction between NK cells and trophoblast cells. Evidence for divergent functional profiles of decidual versus peripheral NK cells.

INT IMMUNOL. 2008 Nov;20(11):1395-405.

6

Stifanese R, Averna M, De Tullio R, Salamino F, Cantoni C, Mingari M.C., Prato C, Pontremoli

S, Melloni E.

Role of the calpain-calpastatin system in the density-dependent growth arrest.

ARCH. BIOCHEM. BIOPHYS. 2008, 15:479(2):145-52

7

Catassi A, Paleari L, Servent D, Sessa F, Dominioni L, Ognio E, Cilli M, Vacca P, Mingari M.C., Gaudino G, Bertino P, Paolucci M, Calcaterra A, Cesario A, Granone P, Costa R, Ciarlo M, Alama A, Russo P.

Targeting alpha7-nicotinic receptor for the treatment of pleural mesothelioma.

EUR J CANCER. 2008, 44:2296-311.

8

Giuliani M, Giron-Michel J, Negrini S, Vacca P, Durali D, Caignard A, Le Bousse-Kerdiles C, Chouaib S, Devocelle A, Bahri R, Durrbach A, Taoufik Y, Ferrini S, Croce M, Mingari MC, Moretta L, Azzarone B.
Generation of a novel regulatory NK cell subset from peripheral blood CD34+ progenitors promoted by membrane-bound IL-15.
PLoS ONE. 2008 May 21;3(5):e2241

9

Pende D, Marcenaro S, Falco M, Martini S, Bernardo ME, Montagna D, Romeo E, Cagnet C, Martinetti M, Maccario R, Mingari MC, Vivier E, Moretta L, Locatelli F, Moretta A.
Anti-leukemia activity of alloreactive NK cells in KIR ligand-mismatched haploidentical HSCT for pediatric patients: evaluation of the functional role of activating KIR and re-definition of inhibitory KIR specificity.
BLOOD. 2009 Mar 26;113(13):3119-29.

10

De Maria A, Ugolotti E, Rutjens E, Mazza S, Radic L, Faravelli A, Koopman G, Di Marco E,
Costa P, Ensoli B, Cafaro A, Mingari MC, Moretta L, Heeney J, Biassoni R.
NKp44 expression, phylogenesis and function in non-human primate NK cells
INT IMMUNOL. 2009 Mar;21(3):245-55.

11

Sensi M, Pietra G, Molla A, Nicolini G, Vegetti C, Bersani I, Millo E, Weiss E, Moretta L, Mingari MC, Anichini A
Peptides with dual binding specificity for HLA-A2 and HLA-E are encoded by alternatively spliced isoforms of the antioxidant enzyme peroxiredoxin 5.
INT IMMUNOL. 2009 Mar;21(3):257-68.

12

Pietra G.,Manzini C., Vitale M.,Balsamo M., Ognio E., Boitano M., Queirolo P., Moretta L. and Mingari M.C.
Natural Killer cells kill human melanoma cells with characteristics of cancer stem cells
INT. IMMUNOL. 2009 Jul; 21(7):793-801

13

Locatelli F, Pende D, Maccario R, Mingari MC, Moretta A, Moretta L.
Haploidentical hemopoietic stem cell transplantation for the treatment of high-risk leukemias: how NK cells make the difference
CLIN IMMUNOL. 2009 Nov;133(2):171-8.

14

Morandi B, Mortara L, Carrega P, Cantoni C, Costa G, Accolla RS, Mingari MC, Ferrini S, Moretta L, Ferlazzo G.
NK cells provide helper signal for CD8+ T cells by inducing the expression of

membrane-bound IL-15 on DCs
INT IMMUNOL. 2009 May;21(5):599-606.

15

Balsamo M, Zambello R, Teramo A, Pedrazzi M, Sparatore B, Scordamaglia F, Pende D, Mingari MC, Moretta L, Moretta A, Semenzato G, Vitale M.
Analysis of NK cell/DC interaction in NK-type lymphoproliferative disease of granular lymphocytes (LDGL): role of DNAM-1 and NK p30
EXP HEMATOL. 2009 Oct;37(10):1167-75.

16

Pietra G, Romagnani C, Moretta L, Mingari MC.
HLA-E and HLA-E- bound peptides: recognition by subsets of NK and T cells
CURR PHARM DES. 2009;15(28):3336-44

17

Balsamo M, Zambello R, Teramo A, Pedrazzi M, Sparatore B, Scordamaglia F, Pende D, Mingari MC, Moretta L, Moretta A, Semenzato G, Vitale M.
Analysis of NK cell/DC interaction in NK-type lymphoproliferative disease of granular lymphocytes (LDGL): role of DNAM-1 and NKp30.
EXP HEMATOL. 2009;37(10):1167-75.

18

Pietra G, Manzini C, Vitale M, Balsamo M, Ognio E, Boitano M, Queirolo P, Moretta L, Mingari MC.
Natural killer cells kill human melanoma cells with characteristics of cancer stem cells.
INT IMMUNOL. 2009 Jul;21(7):793-801

19

Locatelli F, Pende D, Maccario R, Mingari MC, Moretta A, Moretta L.
Haploidentical hemopoietic stem cell transplantation for the treatment of high-risk leukemias: how NK cells make the difference.
CLIN IMMUNOL. 2009 Nov;133(2):171-8.

20

Morandi B, Mortara L, Carrega P, Cantoni C, Costa G, Accolla RS, Mingari MC, Ferrini S, Moretta L, Ferlazzo G.
NK cells provide helper signal for CD8+ T cells by inducing the expression of membrane-bound IL-15 on DCs.
INT IMMUNOL. 2009 May;21(5):599-606

21

Sensi M, Pietra G, Molla A, Nicolini G, Vegetti C, Bersani I, Millo E, Weiss E, Moretta L, Mingari MC, Anichini A.
Peptides with dual binding specificity for HLA-A2 and HLA-E are encoded by alternatively spliced isoforms of the antioxidant enzyme peroxiredoxin 5.
INT IMMUNOL. 2009 Mar;21(3):257-68

22

Fodor E, Barabino S, Montaldo E, Mingari MC, Rolando M.
Quantitative evaluation of ocular surface inflammation in patients with different

grade of conjunctivochalasis
CURR EYE RES. 2010 Aug;35(8):665-9

23

Barabino S, Montaldo E, Solignani F, Valente C, Mingari MC, Rolando M.
Immune response in the conjunctival epithelium of patients with dry eye.
EXP EYE RES. 2010; 91(4); 524-529.

24

Laurent S, Carrega P, Saverino D, Piccioli P, Camoriano M, Morabito A, Dozin B, Fontana V, Simone R, Mortara L, Mingari MC, Ferlazzo G, Pistillo MP.
CTLA-4 is expressed by human monocyte-derived dendritic cells and regulates their functions.
HUM IMMUNOL. 2010; 71(10) 934-941.

25

Pietra G, Romagnani C, Manzini C, Moretta L, Mingari MC.
The emerging role of HLA-E-restricted CD8+ T lymphocytes in the adaptive immune response to pathogens and tumors.
J BIOMED BIOTECHNOL. 2010; 2010:907092.

26

Falco M, Romeo E, Marcenaro S, Martini S, Vitale M, Bottino C, Mingari MC, Moretta L, Moretta A, Pende D.
Combined genotypic and phenotypic killer cell Ig-like receptor analyses reveal KIR2DL3 alleles displaying unexpected monoclonal antibody reactivity: identification of the amino acid residues critical for staining.
J IMMUNOL. 2010 Jul 1;185(1):433-41.

27

Montalto E, Mangraviti S, Costa G, Carrega P, Morandi B, Pezzino G, Bonaccorsi I, Cancellieri A, Mingari MC, Mesiti M, Ferlazzo G, Melioli G.
Seroma fluid subsequent to axillary lymph node dissection for breast cancer derives from an accumulation of afferent lymph.
IMMUNOL LETT. 2010 Jun 15;131(1):67-72

28

Moretta L, Locatelli F, Pende D, Mingari MC, Moretta A.
Natural killer alloeffector responses in haploidentical hemopoietic stem cell transplantation to treat high-risk leukemias.
TISSUE ANTIGENS. 2010 Feb;75(2):103-9.

29

Rutjens E, Mazza S, Biassoni R, Koopman G, Ugolotti E, Fogli M, Dubbes R, Costa P, Mingari MC, Greenwood EJ, Moretta L, De Maria A, Heeney JL.
CD8+ NK cells are predominant in chimpanzees, characterized by high NCR expression and cytokine production, and preserved in chronic HIV-1 infection.
EUR J IMMUNOL. 2010 May;40(5):1440-50.

30

Vacca P, Cantoni C, Vitale M, Prato C, Canegallo F, Fenoglio D, Ragni N,

Moretta L, Mingari MC.

Crosstalk between decidual NK and CD14+ myelomonocytic cells results in induction of Tregs and immunosuppression.

PROC. NATL. ACAD. SCI. USA. Jun 29;107(26):11918-11923, 2010.

31

Bonaccorsi I, Cantoni C, Carrega P, Oliveri D, Lui G, Conte R, Navarra M, Cavaliere R, Traggiai E, Gattorno M, Martini A, Mingari MC, Moretta A, Ferlazzo G.

The immune inhibitory receptor LAIR-1 is highly expressed by plasmacytoid dendritic cells and acts complementary with NKp44 to control IFN- α production.

PLOS ONE. 2010 Nov 30;5(11):e15080

32

Moretta, L., Locatelli, L., Pende, D., Marcenaro, E., Mingari, M.C., and Moretta, A.

Killer ig-like receptor-mediated control of natural killer cell alloreactivity in haploidentical hematopoietic stem cell transplantation.

BLOOD 2011 Jan 20;117(3):764-771.

33

Vacca, P., Vitale, C., Montaldo, E., Conte, R., Cantoni, C., Fulcheri, E., Darretta, V., Moretta, L., and Mingari, M.C.

CD34⁺ haematopoietic precursors are present in human decidua and differentiate into Natural Killer (NK) cells upon interaction with stromal cells.

PROC. NATL. ACAD. SCI. USA. 2011 Feb 8;108(6):2402-2407.

34

Moretta, L., Locatelli, F., Pende, D., Sivori, S., Falco, M., Bottino, C., Mingari, M.C., Moretta, A.

Human NK receptors: from the molecules to the therapy of high risk leukemias.

FEBS Lett. 2011 Jun 6;585(11):1563-1567.

35

Vacca, P., Moretta, L., Moretta, A., and Mingari, M.C.

Human Natural Killer cells in pregnancy: origin, phenotypic features and regulatory function.

TRENDS IMMUNOL. 2011. Vol.32(n.11):517-523.

36

Righi E, Kashiwagi S, Yuan J, Santosuosso M, Leblanc P, Ingraham R, Forbes B, Edelblute B, Collette B, Xing D, Kowalski M, Mingari MC, Vianello F, Birrer M, Orsulic S, Dranoff G, Poznansky MC.

CXCL12/CXCR4 blockade induces multimodal antitumor effects that prolong survival in an immunocompetent mouse model of ovarian cancer.

CANCER RES. 2011 Aug 15;71(16):5522-34.

37

Orecchia P, Conte R, Balza E, Castellani P, Borsi L, Zardi L, Mingari MC, Carnemolla B.

Identification of a novel cell binding site of periostin involved in tumor growth

EUR J CANCER. 2011 Sep;47(14):2221-9.

38

Pietra G, Manzini C, Rivara S, Vitale M, Cantoni C, Petretto A, Balsamo M, Conte R, Benelli R, Minghelli S, Solari N, Gualco M, Queirolo P, Moretta L, Mingari MC. Melanoma cells inhibit Natural killer cell function by modulating the expression of activating receptors and cytolytic activity. CANCER RES. 2012 Mar 15;72(6):1407-15.

39

Montaldo E, Vitale C, Cottalasso F, Conte R, Glatzer T, Ambrosini P, Moretta L, Mingari MC. Human NK cells at early stages of differentiation produce CXCL8 and express CD161 molecule that functions as an activating receptors. BLOOD. 2012 Apr 26;119(17):3987-96.

40

Balsamo M, Vermi W, Parodi M, Pietra G, Manzini C, Queirolo P, Lonardi S, Augugliaro R, Moretta A, Facchetti F, Moretta L, Mingari MC, Vitale M. Melanoma cells become resistant to NK-cell-mediated killing when exposed to NK-cell numbers compatible with NK-cell infiltration in the tumor. EUR J IMMUNOL. 2012 Jul;42(7):1833-42.

41

Morandi B, Mortara L, Chiossone L, Accolla RS, Mingari MC, Moretta L, Moretta A, Ferlazzo G. Dendritic cell editing by activated natural killer cells results in a more protective cancer-specific immune response PLOS ONE. 2012;7(6):e39170.

42

Pietra G, Vitale M, Moretta L, Mingari MC. How melanoma cells inactivate NK cells ONCOIMMUNOLOGY. 2012 Sep 1;1(6):974-975.

43

Balsamo M, Pietra G, Vermi W, Moretta L, Mingari MC, Vitale M. Melanoma immunoediting by NK cells ONCOIMMUNOLOGY. 2012 Dec 1;1(9):1607-1609.

44

Vacca P, Martini S, Garelli V, Passalacqua G, Moretta L, Mingari MC. NK cells from malignant pleural effusion are not anergic but produce cytokines and display strong antitumor activity on short-term IL-2 activation. EUR J IMMUNOL. 2013 Feb;43(2):550-61

45

Heatley SL, Pietra G, Lin J, Widjaja JM, Harpur CM, Lester S, Rossjohn J, Szer J, Schwarzer A, Bradstock K, Bardy PG, Mingari MC, Moretta L, Sullivan LC, Brooks AG.

Polymorphism in human cytomegalovirus UL 40 impacts on recognition of HLA-E by natural killer cells

J BIOL CHEM. 2013 Mar 22;288(12):8679-90.

46

Orecchia P, Conte R, Balza E, Petretto A, Mauri P, Mingari MC, Carnemolla B. A novel human anti-syndecan-1 antibody inhibits vascular maturation and tumour growth in melanoma.

EUR J CANCER. 2013 May;49(8):2022-33.

47

Locatelli F, Pende D, Mingari MC, Bertaina A, Falco M, Moretta A, Moretta L. Cellular and molecular basis of haploidentical hematopoietic stem cell transplantation in the successful treatment of high-risk leukemias: role of alloreactive NK cells.

FRONT IMMUNOL. 2013 Feb 1;4:15.

48

Vacca P, Maria Cristina Mingari, Lorenzo Moretta. Natural killer cells in human pregnancy.

J REPROD IMMUNOL. 2013 Mar;97(1):14-9

49

Vacca P, Stefania Martini, Maria C. Mingari and Lorenzo Moretta.

NK cells from malignant pleural effusions are potent antitumor effectors: A clue for adoptive immunotherapy?

ONCOIMMUNOLOGY. 2013 Apr 1;2(4):e23638.

50

Carrega P, Bonaccorsi I, Di Carlo E, Morandi B, Paul P, Rizzello V, Cipollone G, Navarra G, Mingari MC, Moretta L, Ferlazzo G.

CD56(bright)Perforin(low) noncytotoxic human NK cells are abundant in both healthy and neoplastic solid tissues and recirculate to secondary lymphoid organs via afferent lymph.

J IMMUNOL. 2014 Apr 15;192(8):3805-15

51

Moretta L, Pietra G, Montaldo E, Vacca P, Pende D, Falco M, Del Zotto G, Locatelli F, Moretta A, Mingari MC.

Human NK Cells: From Surface Receptors to the Therapy of Leukemias and Solid Tumors.

FRONT IMMUNOL. 2014 Mar 7;5:87.

52

Croxatto D, Vacca P, Canegallo F, Conte R, Venturini PL, Moretta L, Mingari MC.

Stromal cells from human decidua exert a strong inhibitory effect on NK cell function and dendritic cell differentiation.

54.

Montaldo E, Vacca P, Moretta L, Mingari MC.
Development of human natural killer cells and other innate lymphoid cells.
SEMIN IMMUNOL. 2014 Apr;26(2):107-13.

55

Meazza R, Tuberosa C, Cetica V, Falco M, Loiacono F, Parolini S, Micalizzi C, Moretta A, Mingari MC, Moretta L, Bottino C, Aricò M, Pende D.
XLP1 inhibitory effect by 2B4 does not affect DNAM-1 and NKG2D activating pathways in NK cells.
EUR J IMMUNOL. 2014 May;44(5):1526-34

56

Rizzo R, Audrito V, Vacca P, Rossi D, Brusa D, Stignani M, Bortolotti D, D' Arena G, Coscia M, Laurenti L, Forconi F, Gaidano G, Mingari MC, Moretta L, Malavasi F, Deaglio S.
HLA-G is a component of the CLL escape repertoire to generate immune suppression: impact of HLA-G 14 bp (rs66554220) polymorphism.
HAEMATOLOGICA. 2014 May;99(5):888-96

57

Chiossone L, Vacca P, Orecchia P, Croxatto D, Damonte P, Astigiano S, Barbieri O, Bottino C, Moretta L, Mingari MC.
In vivo generation of decidual natural killer cells from resident hematopoietic progenitors.
HAEMATOLOGICA. 2014 Mar;99(3):448-57.

58

Bonaccorsi I, Morandi B, Antsiferova O, Costa G, Oliveri D, Conte R, Pezzino G, Vermiglio G, Anastasi GP, Navarra G, Münz C, Di Carlo E, **Mingari MC**, Ferlazzo G.
Membrane transfer from tumor cells overcomes deficient phagocytic ability of plasmacytoid dendritic cells for the acquisition and presentation of tumor antigens.
J IMMUNOL. 2014 Jan 15;192(2):824-32.

59

Meazza R, Tuberosa C, Cetica V, Falco M, Parolini S, Grieve S, Griffiths GM, Sieni E, Marcenaro S, Micalizzi C, Montin D, Fagioli F, Moretta A, **Mingari MC**, Moretta L, Notarangelo LD, Bottino C, Aricò M, Pende D.
Diagnosing XLP1 in patients with hemophagocytic lymphohistiocytosis.
J ALLERGY CLIN IMMUNOL. 2014 Dec;134(6):1381-1387.

60

Giannoni P, Pietra G, Travaini G, Quarto R, Shyti G, Benelli R, Ottaggio L, **Mingari MC**, Zupo S, Cutrona G, Pierri I, Balleari E, Pattarozzi A, Calvaruso M, Tripodo C, Ferrarini M, de Toter D.
Chronic lymphocytic leukemia nurse-like cells express hepatocyte growth factor receptor (c-MET) and indoleamine 2,3-dioxygenase and display features of immunosuppressive type 2 skewed macrophages.

HAEMATOLOGICA. 2014 Jun;99(6):1078-87.

64

Vitale M, Cantoni C, Pietra G, **Mingari MC**, Moretta L.
Effect of tumor cells and tumor microenvironment on NK-cell function.
EUR J IMMUNOL. 2014 Jun;44(6):1582-92

65

Moretta L, Montaldo E, Vacca P, Del Zotto G, Moretta F, Merli P, Locatelli F,
Mingari MC.
Human natural killer cells: origin, receptors, function, and clinical applications.
INT ARCH ALLERGY IMMUNOL. 2014;164(4):253-64

67

Montaldo E, Teixeira-Alves LG, Glatzer T, Durek P, Stervbo U, Hamann W,
Babic M, Paclik D, Stölzel K, Gröne J, Lozza L, Juelke K, Matzmohr N, Loiacono
F, Petronelli F, Huntington ND, Moretta L, **Mingari MC**, Romagnani C.
Human ROR γ t(+)CD34(+) cells are lineage-specified progenitors of group 3
ROR γ t(+) innate lymphoid cells.
IMMUNITY. 2014 Dec 18;41(6):988-1000.

66

Vitale C, Ambrosini P, Montaldo E, Ballerini F, Moretta L, **Mingari MC**.
IL-1 β -releasing human acute myeloid leukemia blasts modulate natural killer cell
differentiation from CD34+ precursors.
HAEMATOLOGICA. 2015 Feb;100(2):e42-5

63

Vacca P, Montaldo E, Croxatto D, Loiacono F, Canegallo F, Venturini PL,
Moretta L, **Mingari MC**. Identification of diverse innate lymphoid cells in human
decidua.
MUCOSAL IMMUNOL. 2015 Mar;8(2):254-64. doi: 10.1038/mi.2014.63. Epub
2014 Jul 23.

68

Caccamo N, Pietra G, Sullivan LC, Brooks AG, Prezzemolo T, La Manna MP, Di
Liberto D, Joosten SA, van Meijgaarden KE, Di Carlo P, Titone L, Moretta L,
Mingari MC, Ottenhoff TH, Dieli F.
Human CD8 T lymphocytes recognize Mycobacterium tuberculosis antigens
presented by HLA-E during active tuberculosis and express type 2 cytokines.
EUR J IMMUNOL. 2015 Apr;45(4):1069-81

69

Ambrosini P, Loiacono F, Conte R, Moretta L, Vitale C, **Mingari MC**.
IL-1 β inhibits ILC3 while favoring NK-cell maturation of umbilical cord blood
CD34+ precursors.
EUR J IMMUNOL. 2015 Apr 7. doi: 10.1002/eji.201445326. [Epub ahead of
print]

70

Orecchia P., Conte R., Balza E., Pietra G., **Mingari M.C.** and Carnemolla B.
Targeting Syndecan-1, a molecule implicated in the process of vasculogenic

mimicry, enhances the therapeutic efficacy of the L19-IL2 immunocytokine in human melanoma xenografts
ONCOTARGET (in press)

71

NCR(+)ILC3 concentrate in human lung cancer and associate with intratumoral lymphoid structures Carrega P, Loiacono F, Di Carlo E, Scaramuccia A, Mora M, Conte R, Benelli R, Spaggiari GM, Cantoni C, Campana S, Bonaccorsi I, Morandi B, Truini M, Mingari MC, Moretta L, Ferlazzo G. Nat Commun. 2015 Sep 23;6:8280.